Here’s a roundup of companies announcing new distribution deals.
- TechniScan inks deal with Womens3D worth up to $11.5 million
Salt Lake City-based TechniScan Inc. (OTC:TSNI) signed agreements for manufacturing and use of trademarks with Austin, Texas-based Womens3D Inc. These agreements follow a product development agreement signed between the two companies in January in which the companies agreed to jointly develop a specialized version of TechniScan’s Warm Bath Ultrasound system specifically for Womens3D target market of women’s specific health practices such as OB/GYN and general practice offices. Under the terms of the manufacturing agreement, TechniScan will be the exclusive manufacturer and supplier of the products and Womens3D will receive a license to sell the product to its target market. The license becomes exclusive upon certain conditions being met, including payment of at least $1.5 million to TechniScan in connection with the initial design and development of the product. Womens3D also committed to purchase at least $10 million of TechniScan’s products during the three years following approval from the Food & Drug Administration.
- Royal Fornia licenses Masimo pulse CO-oximetry
Irvine, Calif.-based Masimo (NSDQ:MASI) and Guangdong Province, China-based Royal Fornia Electronic Device Co. Ltd. jointly signed a licensing agreement to integrate Masimo rainbow SET Pulse CO-Oximetry technology into Royal Fornia’s new generation of multiparameter patient monitors — enabling advanced noninvasive blood constituent measurements that help clinicians to detect and treat life-threatening conditions earlier. Having recently received State Food and Drug Administration approval for Masimo rainbow SET parameters in China, Royal Fornia establishes itself as one of the first domestic Chinese medical device manufacturers to commercially incorporate Masimo’s breakthrough noninvasive blood constituent measurement capabilities.
- Greatbatch Medical and Boston Scientific extend agreement
Greatbatch Inc. (NYSE:GB) company Greatbatch Medical signed a five-year agreement with Boston Scientific Corp.’s (NYSE:BSX) Cardiology, Rhythm and Vascular Group. The new deal replaces the previous contract between the two companies, and expands the depth of the relationship by adding multiple new product lines to the agreement. Clarence, N.Y.-based Greatbatch Medical and Natick, Mass.-based Boston Scientific have additional agreements pertaining to other products and systems. Those contracts remain in place and have not been impacted by this agreement.
- SoftGenetics to supply forensic analysis software for IntegenX’s DNA system
IntegenX Inc. and SoftGenetics LLC announced that their GeneMarker HID forensics software will power the data analysis feature of IntegenX’s Apollo 200 RapidHIT DNA Profiling system for human identification. The incorporated software will enable the integrated system to produce unique human DNA profiles in standardized formats compatible with human identification database search systems. IntegenX is developing the Apollo 200 RapidHIT DNA Profiling system for deployment with law enforcement agencies and the U.S. Departments of Defense and Homeland Security. The system automatically prepares, processes, and sequences DNA from cheek swabs and other suitable human tissue samples. With the incorporation of GeneMarker HID software, the integrated system will automate and speed up the production of critical information for border security operations, crime scene analysis, paternity and other kinship determinations and other human identification needs.
- GE Healthcare and Capsule ink deal
General Electric Co.’s (NYSE:GE) healthcare unit and Capsule Tech Inc. announced a relationship to help speed the access of clinical information to caregivers. The companies will align GE Healthcare’s CARESCAPE portfolio of patient monitors with Capsule;s Enterprise Device Connectivity Solution and Mobile Vitals Plus applications. Capsule’s connectivity solution improves medical device information flow throughout the hospital — from critical care, to the OR, ED and med-surg units. Under the terms of the arrangement, GE Healthcare will resell Capsule’s products. As an initial step in the relationship, hospitals can now leverage GE Healthcare’s vital signs monitors with Capsule’s Mobile Vitals Plus application, which helps caregivers capture vital signs for multiple patients, validate these clinical measurements at the point of care and automatically send them to the EMR. Mobile Vitals Plus connectivity with GE Healthcare’s monitors and EMRs can help clinicians make efficient clinical decisions, supporting quality of care.